Omega Therapeutics, Inc. financial data

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 14 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 253% % -50%
Debt-to-equity 417% % 380%
Return On Equity -213% % -98%
Return On Assets -41% % 29%
Operating Margin -916% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55,366,213 shares 0.41%
Common Stock, Shares, Outstanding 55,159,219 shares 0.03%
Common Stock, Value, Issued $55,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 55,155,583 shares 0.03%
Weighted Average Number of Shares Outstanding, Diluted 55,155,583 shares 0.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $8,094,000 USD 214%
Research and Development Expense $56,692,000 USD -36%
General and Administrative Expense $25,553,000 USD -5%
Operating Income (Loss) $74,151,000 USD 33%
Nonoperating Income (Expense) $1,059,000 USD -57%
Net Income (Loss) Attributable to Parent $73,092,000 USD 32%
Earnings Per Share, Basic -1 USD/shares 37%
Earnings Per Share, Diluted -1 USD/shares 37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $30,377,000 USD -63%
Assets, Current $38,953,000 USD -62%
Property, Plant and Equipment, Net $4,498,000 USD -16%
Operating Lease, Right-of-Use Asset $109,245,000 USD -0.77%
Other Assets, Noncurrent $31,000 USD -74%
Assets $152,727,000 USD -30%
Accounts Payable, Current $1,434,000 USD -40%
Employee-related Liabilities, Current $2,664,000 USD -29%
Accrued Liabilities, Current $4,650,000 USD -38%
Liabilities, Current $24,173,000 USD -9.9%
Operating Lease, Liability, Noncurrent $100,627,000 USD 1.9%
Other Liabilities, Noncurrent $4,797,000 USD 1311%
Liabilities $141,184,000 USD -0.41%
Retained Earnings (Accumulated Deficit) $387,512,000 USD -23%
Stockholders' Equity Attributable to Parent $11,543,000 USD -85%
Liabilities and Equity $152,727,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,805,000 USD 58%
Net Cash Provided by (Used in) Financing Activities $1,070,000 USD -103%
Net Cash Provided by (Used in) Investing Activities $4,465,000 USD -80%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 55,159,219 shares 0.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,410,000 USD -125%
Interest Paid, Excluding Capitalized Interest, Operating Activities $484,000 USD 25%
Operating Lease, Liability $112,546,000 USD 1.1%
Depreciation $1,840,000 USD 26%
Payments to Acquire Property, Plant, and Equipment $535,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $73,006,000 USD 32%
Lessee, Operating Lease, Liability, to be Paid $199,701,000 USD -2.6%
Property, Plant and Equipment, Gross $11,765,000 USD 2.9%
Operating Lease, Liability, Current $11,919,000 USD -5.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $12,819,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $12,492,000 USD -2.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $87,155,000 USD -7%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,155,000 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $13,501,000 USD
Operating Lease, Payments $2,335,000 USD 511%
Additional Paid in Capital $399,000,000 USD 2.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $8,480,000 USD -3.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%